Roivant Sciences Ltd. (ROIV)’s Pulmonary Hypertension Breakthrough Could Transform Its Growth Story
Roivant Sciences Ltd. (NASDAQ:ROIV) shares surged 18% on September 8 after the biotech company reported strong Phase 2 results for an experimental treatment for pulmonary hypertension.






